Aug 19, 2020

PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Initiated Phase 3 SHIELD I Trial for D-PLEX 100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX 100   from FDA Presented Positive Phase 2 Results of D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery at ASCRS Meeting Completed Initial Public Offering in
Aug 05, 2020

PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020

PETAH TIKVA, Israel , Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report
Aug 03, 2020

PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

PETAH TIKVA, Israel , Aug. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX 100 has
Jul 27, 2020

PolyPid to Present Phase 2 Results of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions

PETAH TIKVA, Israel , July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that Dr.
Jul 01, 2020

PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

Petah Tikva, Israel – July 1 st , 2020 –  PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical- stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been
Jun 30, 2020

PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Petah Tikva, Israel – June 30, 2020 – PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the closing of its initial public offering of
Jun 26, 2020

PolyPid Ltd. Announces Pricing of Initial Public Offering

Petah Tikva, Israel – June 26, 2020  –  PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the pricing of its initial public offering of
Feb 27, 2020

PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Sternal Wound Infection Post-Cardiac Surgery

Petah Tikva, Israel, February 27, 2020 —  PolyPid Ltd. , a Phase 3 clinical-stage  biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been enrolled and

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >